ABLYNX'S ANTI-IL-6R NANOBODY, ALX-0061, SHOWS EXCELLENT 24 WEEK SAFETY AND EFFICACY RESULTS IN A PHASE II CLINICAL TRIAL IN RHEUMATOID ARTHRITIS

World News: . []

ACR20 ACR50 and ACR70 scores of up to 100 75 and 63 respectively Up to 75 of patients in DAS28 remission Attractive safety profile at all administered doses No anti-drug antibodies detected No disease progression as determined by MRI ra...

More news and information about Ablynx

Published By:

Thomson Reuters: 06:30 GMT Wednesday 13th February 2013

Published: .

Search for other references to "ablynx" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers